CORAL SPRINGS, FL--(Marketwired - January 07, 2014) - Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that they have begun shipping the initial product orders to MyNyloxin, a new company that has the exclusive rights to market and distribute Nutra Pharma’s over-the-counter (OTC) pain reliever, Nyloxin®, in the Network Marketing channel. Nutra Pharma previously announced the launch of the MyNyloxin website that allows for product sales and information as well as allowing distributors to sign up and view the Network Marketing opportunity. Nutra Pharma will continue to market the products through their retail and Direct Response distributors.
“Our Independent Entrepreneurs are excited to begin distributing Nyloxin and sharing this opportunity,” stated Dalton Johnson, CEO of MyNyloxin.com. “MyNyloxin.com is comprised of a group of professional marketers whom have come together on a mission to spread awareness of Nyloxin,” he continued. “By providing access to a superior pain relief product that customers need and can trust and by providing an innovative network marketing program which offers a fair and balanced compensation plan for both the average and ambitious MyNyloxin Independent Entrepreneur (MIE), we believe that we will change lives for the better,” he concluded.
In August 2013, Nutra Pharma announced the formation of MyNyloxin.com, a new Multi-Level Marketing company that would act as the exclusive Nyloxin® Distributor in the Network Marketing channel. The pre-launch began in late December with the initial orders shipping today. The launch is continuing and includes webinars, internet, radio and television advertising.
“We’re very happy with the relationship that we’ve created with MyNyloxin,” commented Rik J Deitsch, CEO of Nutra Pharma. “Network Marketing allows for the rapid distribution of products directly to the end-user and can rapidly provide product sales as well as validity in the form of product user testimonials. We’ve already received very favorable feedback from the MyNyloxin Distributors and expect significant growth as the launch continues,” he concluded.
Nyloxin® is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin® is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin® is also offered in an extra strength formula for more advanced, Stage 3, chronic pain. The Company recently announced the beginning of marketing efforts by New Vitality for the Direct Response and retail marketing of Nyloxin®. New Vitality’s first Nyloxin® television commercials are scheduled to begin shortly.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin®. For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or
http://www.Nyloxin.com.
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected in Nutra Pharma’s (“the Company”) business plan. The delivery of product to MyNyloxin Distributors should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company’s filings may be accessed at the SEC’s Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Digg this 
Bookmark with del.icio.us 
Add to Newsvine
Technorati: anti-inflammatory drugs pharmaceuticals
Help employers find you! Check out all the jobs and post your resume.